The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
DNA methyltransferase Dnmt1 associates with histone deacetylase activity
Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L., & Kouzarides, T. (2000) · Nature Genetics · doi:10.1038/71750 · Cited by 994
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009142 · Cited by 467
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.
Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., & Richardson, B. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.7.2197 · Cited by 420
Deng, C., Lu, Q., Zhang, Z., Rao, T., Attwood, J., Yung, R., & Richardson, B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10833 · Cited by 284
Differential expression of selected histone modifier genes in human solid cancers
Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 259
Epigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236
GRADY, W., RAIPUT, A., LUTTERBAUGH, J., & MARKOWITZ, S. (2001) · Gastroenterology · doi:10.1016/s0016-5085(01)81443-8 · Cited by 224
Hematologic Toxicity of Sodium Valproate
Acharya, S., & Bussel, J. B. (2000) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200001000-00012 · Cited by 220
Chuang, J. C., Yoo, C. B., Kwan, J. M., Li, T. W. H., Liang, G., Yang, A. S., & Jones, P. A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0172 · Cited by 210
Segura-Pacheco, B. A., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Mariscal, I., Chavez, A., Acuña, C., Salazar, A. M., Lizano, M., & Dueñas‐González, A. (2003) · PubMed · Cited by 206
Self-citationBug, G., Ritter, M., Wassmann, B., Schoch, C., Heinzel, T., Schwarz, K., Romanski, A., Kramer, O. H., Kampfmann, M., Hoelzer, D., et al. (2005) · Cancer · doi:10.1002/cncr.21589 · Cited by 184
Sebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
Arce, C., Pérez‐Plasencia, C., González‐Fierro, A., la Cruz-Hernández, E. N. D., Vázquez, A. L. R., Chávez-Blanco, A. D., Trejo‐Becerril, C., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Bargalló, E., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000098 · Cited by 158
Self-citationZambrano, P., Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Cetina, L., Vázquez, A. L. R., Taja‐Chayeb, L., Chávez-Blanco, A. D., Ángeles, E., Cabrera, G., Sandoval, K., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-44 · Cited by 156
Self-citationChávez-Blanco, A. D., Pérez‐Plasencia, C., Pérez‐Cárdenas, E., Legleu, C. E. C., Rangel‐López, E., Segura-Pacheco, B. A., Taja‐Chayeb, L., Trejo‐Becerril, C., González‐Fierro, A., Candelaria, M., et al. (2006) · Cancer Cell International · doi:10.1186/1475-2867-6-2 · Cited by 143
Self-citationSamlowski, W. E., Leachman, S. A., Wade, M. L., Cassidy, P. B., Porter-Gill, P. A., Busby, L. T., Wheeler, R. H., Boucher, K. M., Fitzpatrick, F. A., Jones, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.118 · Cited by 141
Chávez-Blanco, A. D., Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Cetina, L., Candelaria, M., de León, D. F. C., González‐Fierro, A., García‐López, P., Zambrano, P., et al. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-22 · Cited by 129
Self-citationHydralazine target: From blood vessels to the epigenome
Arce, C., Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Candelaria, M., & Dueñnas-Gonzalez, A. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-10 · Cited by 119
Self-citationDrug-induced DNA hypermethylation and drug resistance in human tumors.
Nyce, J. W. (1989) · PubMed · Cited by 119
Bourg, V., Lebrun‐Frénay, C., Chichmanian, R. M., Thomas, P., & Frénay, M. (2001) · Annals of Oncology · doi:10.1023/a:1008331708395 · Cited by 116
Roberti, A., Sala, D. L., & Cinti, C. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20515 · Cited by 107
Segura-Pacheco, B. A., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Chávez-Blanco, A. D., Vázquez, A. L. R., Benı́tez-Bribiesca, L., & Dueñas‐González, A. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-32 · Cited by 93
Self-citationFischer, J. R., Ohnmacht, U., Rieger, N., Žemaitis, M., Stoffregen, C., Kostrzewa, M., Buchholz, E., Manegold, C., & Lahm, H. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.06.017 · Cited by 93
Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells
Nyce, J. W., Liu, L., & Jones, P. A. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.10.4353 · Cited by 84
Buermeyer, A. B., Patten, C. W.-V., Baker, S. M., & Liskay, R. M. (1999) · PubMed · Cited by 68
Qiu, Y.-Y., Mirkin, B. L., & Dwivedi, R. S. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.05.004 · Cited by 55
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Pérez‐Plasencia, C., & Dueñas‐González, A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-27 · Cited by 41
Self-citationDetermination of 5‐methyl‐cytosine and cytosine in tumor DNA of cancer patients
Guerrero, K. S., Vázquez, A. L. R., Segura-Pacheco, B. A., et al. (2005) · Electrophoresis · doi:10.1002/elps.200410040 · Cited by 22
Cytostatic drug treatment causes seeding of gene promoter methylation
Bredberg, A. C. A., & Bodmer, W. F. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.003 · Cited by 19
Cited by
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 499
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Duenas-Gonzalez, A., Candelaria, M., Perez-Plascencia, C., Perez-Cardenas, E., de la Cruz-Hernandez, E., & Herrera, L. A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.11.003 · Cited by 354
Self-citation
Metadata
- Authors
- Candelaria, M., Gallardo-Rincón, D., Arce, C., Cetina, L., Aguilar-Ponce, J. L., Arrieta, Ó., González-Fierro, A., Chávez-Blanco, A., de la Cruz-Hernández, E., Camargo, M. F., Trejo-Becerril, C., Pérez-Cárdenas, E., Pérez-Plasencia, C., Taja-Chayeb, L., Wegman-Ostrosky, T., Revilla-Vazquez, A., & Dueñas-González, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 18
- Issue
- 9
- Pages
- 1529-1538
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2081159709
- Cited by
- 252
- References
- 32
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.